23-valent pneumococcal polysaccharide vaccine (pneumovax-23) Report issue

Active Ingredient History

  • Now
Pneumococcal polysaccharide vaccine (PPSV)—known as Pneumovax 23 (PPV-23)—is the first pneumococcal vaccine derived from a capsular polysaccharide. Its development is an important landmark in medical history. The polysaccharide antigens were used to induce type-specific antibodies that enhanced opsonization, phagocytosis, and killing of Streptococcus pneumoniae (pneumococcal) bacteria by phagocytic immune cells. The pneumococcal polysaccharide vaccine is widely used in high-risk adults. As a result, there have been important reductions in the incidence, morbidity, and mortality from invasive pneumococcal disease.   Wikipedia

More Chemistry
23-valent pneumococcal capsular polysaccharide vaccine | 23-valent pneumococcal polysaccharide vaccine | 23-valent ppv | 23-valent vaccine | pneumo23 | pneumo 23 | pneumo-23 | pneumococcal 23 valent polysaccharide vaccine | pneumococcal polysaccharide vaccine | pneumococcal vaccine, polyvalent | pneumococcal vaccine, polyvalent 23 | pneumovax | pneumovax 23 | pneumovax-23 | pneumovax ii | polysaccharide anti- pneumococcal vaccine | ppsv23 | tetanus toxoid [tt]-containing adsorbed vaccine | v110


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue